Market Research Industry Reports

Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Teva Pharmaceutical Industries Ltd (Teva) is a pharmaceutical company that carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, cancer, womens health and other therapy areas. The company offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 8
List of Figures 10
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 17
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deal Details 27
Asset Purchase 27
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 27
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 28
Labrys Biologics Acquires RN-307 from Pfizer 30
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 31
Venture Financing 33
Auspex Pharma Raises US$20 Million In Series E Financing 33
Labrys Biologics Raises US$31 Million In Series A Financing 35
Auspex Pharma Raises US$25 Million In Series D Financing 37
Auspex Pharma Raises US$1.5 Million In Venture Financing 38
Gamida Cell Raises US$10 Million In Series E Financing 39
Teva Pharma Industries Invests In MultiGene Vascular Systems 41
Private Equity 42
CVC Capital Partners Acquires Women Health Portfolio from Teva Pharma for USD703 Million 42
Partnerships 44
Teva Pharma May Form Joint Venture with Guangzhou Pharma 44
Teva Pharma and Nuvelution Pharma Enter into Agreement 45
AbCellera Biologics Enters into Research Agreement with Teva Pharma 46
Teva Pharma Enters into Distribution Agreement with Celltrion 47
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 48
Teva Pharma and Takeda Pharma Form Joint Venture 49
Teva Pharma Enters into Research Agreement with AbCellera Biologics 51
Egalet Enters into Agreement with Teva Pharma 52
Teva Pharma Partners with University College London and Imanova 53
Teva Pharma Enters into an Agreement with Microchips Biotech 54
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 55
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug 56
Abic Marketing Enters into Agreement with Arena Pharma 57
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 58
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 59
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 60
Champions Enters Into Drug Discovery And Development Agreement With Teva 61
Teva Pharma Plans To Enter Into Partnerships 62
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 63
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 64
Teva Pharma To Form Joint Venture With Handok Pharma 66
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil 67
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 68
Teva Pharma And Proctor & Gamble Finalize Joint Venture 69
Licensing Agreements 71
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 71
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 72
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 73
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 74
Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 75
Watson Labs Enters into Licensing Agreement with CSPC Pharma 76
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 77
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 78
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 79
Auspex Pharma Enters into Licensing Agreement with Imphar 80
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo 81
Pierre Fabre Enters into Licensing Agreement with Medis 82
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 83
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig 85
Equity Offering 86
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 86
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 88
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 90
American Well Raises USD10 Million in Private Placement of Shares 92
Ignyta Raises USD42 Million in Private Placement of Shares 93
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 94
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 96
Auspex Pharma Completes IPO For US$96.6 Million 98
Debt Offering 100
Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 100
Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 101
Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 102
Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 103
Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 104
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 105
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 107
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 109
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 111
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 113
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 115
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 117
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 119
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 121
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 123
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 125
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 127
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 129
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 130
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 131
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million 132
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion 134
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million 136
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion 138
Asset Transactions 140
Biolab Farmaceutica Acquires Brazilian Operation of Actavis 140
NeuroSearch Plans to Sell Its Rights for Pridopidine 141
Super-Pharm May Acquire Ashdod Plant from Teva Pharma Industries 142
Foundation Consumer Healthcare Acquires Women Health Products from Teva Pharma for USD675 Million 143
Teva Pharma May Sell European Oncology and Pain Assets 144
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 145
Teva Pharma May sell Medis Unit 146
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 147
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 148
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 150
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 151
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 152
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 154
Dr. Reddys Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 156
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 157
Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 158
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 159
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 160
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 161
Teva Pharma May Divest its Assets 162
Ferring Pharma Acquires Global Rights to Milprosa from Teva Womens Health 164
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 165
Amneal Pharma Acquires Generic Business of Actavis Australia 166
Teva Pharma Plans to Divest Some Operations 167
Ignyta Acquires Four Oncology R&D Assets from Cephalon 168
ANI Pharma Acquires ANDA from Teva Pharma 170
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs 171
Saniona Acquires Assets from NeuroSearch 172
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 173
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 174
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California 175
CleveXel Pharma Acquires Development Center From Teva Pharma 176
Saniona Acquires Technical Platforms from NeuroSearch 177
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma 178
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 179
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 181
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada 182
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 183
Acquisition 184
NeuroSearch Plans to Sell Itself 184
Allergan to Sell 10% Stake in Teva Pharma 185
Teva Pharma Sells Stake in Mesoblast 186
Jiaxing Yun Shi Tai Yu Investment to Acquire 20% Stake in Tianjin Sinobioway Biomedicine from Tianjin Zhongxin Pharma 187
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 188
Teva Pharma Acquires Anda from Allergan for USD500 Million 189
Teva Pharma, Mylan May Acquire Teut|Pfizer 190
Teva Pharma Acquires Rimsa for USD2.3 Billion 192
Auspex Pharma Acquires Imphar 193
Teva Pharma Acquires Gecko Health Innovations 194
Teva Pharma to Acquire 51% Stake in Immuneering 195
Teva Pharma Acquires Auspex Pharma 196
Teva Pharma Completes Acquisition of Labrys Biologics 198
Teva Pharma Completes Acquisition Of NuPathe 199
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 201
Teva Pharma Completes Acquisition of MicroDose Therapeutx 202
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 203
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 205
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 207
Teva Pharma Rumored To Acquire Amarin 208
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 209
Teva Pharmaceutical Industries Ltd - Key Competitors 211
Teva Pharmaceutical Industries Ltd - Key Employees 212
Teva Pharmaceutical Industries Ltd - Locations And Subsidiaries 214
Head Office 214
Other Locations & Subsidiaries 214
Joint Venture 223
Recent Developments 224
Financial Announcements 224
May 03, 2018: Teva Reports First Quarter 2018 Financial Results 224
Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 229
Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 237
Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 241
May 11, 2017: Teva Reports First Quarter 2017 Financial Results 243
Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 247
Jan 06, 2017: Teva Provides 2017 Financial Outlook 255
Corporate Communications 257
Dec 15, 2017: Drugmaker Teva to cut 14,000 jobs globally 257
Dec 12, 2017: Teva Pharmaceutical Industries: Dr. Yitzhak Peterburg, a member of the Board of Directors Resignation 258
Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 259
Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 260
Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 262
Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 263
Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 264
Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 265
Legal and Regulatory 267
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 267
Product News 268
04/19/2017: Teva to Present Data on Fremanezumab at 69th Annual Meeting of the American Academy of Neurology 268
Product Approvals 269
May 23, 2018: Teva Confirms September PDUFA Date for Fremanezumab 269
Feb 02, 2018: European Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization Application 270
Dec 18, 2017: FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program 271
Oct 17, 2017: Teva Announces Submission of Biologics License Application for Fremanezumab to the U.S. FDA 272
Clinical Trials 273
Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache 273
May 18, 2018: Teva Pharmaceutical Industries Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association 274
May 15, 2018: Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association 276
Apr 17, 2018: Teva to Present New Data on Fremanezumab at 70th Annual Meeting of the American Academy of Neurology 277
Nov 29, 2017: The New England Journal of Medicine Publishes Data from Pivotal Phase III Trial of Fremanezumab for the Preventive Treatment of Chronic Migraine 279
Sep 09, 2017: Teva Showcases Data Demonstrating Potential of Fremanezumab to Address Significant Unmet Need in Patients with Chronic and Episodic Migraine 280
Sep 05, 2017: Teva to Present Fremanezumab Data on Migraine Prevention at the 18th Congress of the International Headache Society 282
Jun 07, 2017: Tevas Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention 284
May 31, 2017: Teva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic Migraine 286
Other Significant Developments 287
Oct 19, 2017: Teva: New Belief-based Patient Support Programme (PSP) Launched for People With Relapsing Multiple Sclerosis 287
Appendix 288
Methodology 288
About GlobalData 288
Contact Us 288
Disclaimer 288

List Of Tables

List of Tables
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Teva Pharmaceutical Industries Ltd, Deals By Therapy Area, 2012 to YTD 2018 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 17
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 27
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 28
Labrys Biologics Acquires RN-307 from Pfizer 30
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 31
Auspex Pharma Raises US$20 Million In Series E Financing 33
Labrys Biologics Raises US$31 Million In Series A Financing 35
Auspex Pharma Raises US$25 Million In Series D Financing 37
Auspex Pharma Raises US$1.5 Million In Venture Financing 38
Gamida Cell Raises US$10 Million In Series E Financing 39
Teva Pharma Industries Invests In MultiGene Vascular Systems 41
CVC Capital Partners Acquires Women Health Portfolio from Teva Pharma for USD703 Million 42
Teva Pharma May Form Joint Venture with Guangzhou Pharma 44
Teva Pharma and Nuvelution Pharma Enter into Agreement 45
AbCellera Biologics Enters into Research Agreement with Teva Pharma 46
Teva Pharma Enters into Distribution Agreement with Celltrion 47
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 48
Teva Pharma and Takeda Pharma Form Joint Venture 49
Teva Pharma Enters into Research Agreement with AbCellera Biologics 51
Egalet Enters into Agreement with Teva Pharma 52
Teva Pharma Partners with University College London and Imanova 53
Teva Pharma Enters into an Agreement with Microchips Biotech 54
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 55
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug 56
Abic Marketing Enters into Agreement with Arena Pharma 57
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 58
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 59
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 60
Champions Enters Into Drug Discovery And Development Agreement With Teva 61
Teva Pharma Plans To Enter Into Partnerships 62
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 63
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 64
Teva Pharma To Form Joint Venture With Handok Pharma 66
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil 67
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 68
Teva Pharma And Proctor & Gamble Finalize Joint Venture 69
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 71
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 72
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 73
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 74
Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 75
Watson Labs Enters into Licensing Agreement with CSPC Pharma 76
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 77
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 78
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 79
Auspex Pharma Enters into Licensing Agreement with Imphar 80
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo 81
Pierre Fabre Enters into Licensing Agreement with Medis 82
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 83
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig 85
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 86
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 88
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 90
American Well Raises USD10 Million in Private Placement of Shares 92
Ignyta Raises USD42 Million in Private Placement of Shares 93
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 94
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 96
Auspex Pharma Completes IPO For US$96.6 Million 98
Teva Pharma Prices Private Placement of 6% Notes Due 2024 for USD1.25 Billion 100
Teva Pharma Prices Private Placement of 6.75% Notes Due 2028 for USD1.25 Billion 101
Teva Pharma Prices Private Placement of 3.25% Notes Due 2022 for USD866.3 Million 102
Teva Pharma Prices Private Placement of 4.5% Notes Due 2025 for USD1,113.8 Million 103
Teva Pharma Plans to Raise USD5,000 Million in Public Offering of Debt Securities 104
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 105
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 107
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 109
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 111
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 113
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 115
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 117
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 119
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 121
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 123
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 125
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 127
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 129
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 130
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 131
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million 132
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion 134
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million 136
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion 138
Biolab Farmaceutica Acquires Brazilian Operation of Actavis 140
NeuroSearch Plans to Sell Its Rights for Pridopidine 141
Super-Pharm May Acquire Ashdod Plant from Teva Pharma Industries 142
Foundation Consumer Healthcare Acquires Women Health Products from Teva Pharma for USD675 Million 143
Teva Pharma May Sell European Oncology and Pain Assets 144
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 145
Teva Pharma May sell Medis Unit 146
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 147
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 148
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 150
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 151
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 152
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 154
Dr. Reddys Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 156
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 157
Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 158
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 159
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 160
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 161
Teva Pharma May Divest its Assets 162
Ferring Pharma Acquires Global Rights to Milprosa from Teva Womens Health 164
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 165
Amneal Pharma Acquires Generic Business of Actavis Australia 166
Teva Pharma Plans to Divest Some Operations 167
Ignyta Acquires Four Oncology R&D Assets from Cephalon 168
ANI Pharma Acquires ANDA from Teva Pharma 170
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs 171
Saniona Acquires Assets from NeuroSearch 172
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 173
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 174
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California 175
CleveXel Pharma Acquires Development Center From Teva Pharma 176
Saniona Acquires Technical Platforms from NeuroSearch 177
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma 178
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 179
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 181
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada 182
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 183
NeuroSearch Plans to Sell Itself 184
Allergan to Sell 10% Stake in Teva Pharma 185
Teva Pharma Sells Stake in Mesoblast 186
Jiaxing Yun Shi Tai Yu Investment to Acquire 20% Stake in Tianjin Sinobioway Biomedicine from Tianjin Zhongxin Pharma 187
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 188
Teva Pharma Acquires Anda from Allergan for USD500 Million 189
Teva Pharma, Mylan May Acquire Teut|Pfizer 190
Teva Pharma Acquires Rimsa for USD2.3 Billion 192
Auspex Pharma Acquires Imphar 193
Teva Pharma Acquires Gecko Health Innovations 194
Teva Pharma to Acquire 51% Stake in Immuneering 195
Teva Pharma Acquires Auspex Pharma 196
Teva Pharma Completes Acquisition of Labrys Biologics 198
Teva Pharma Completes Acquisition Of NuPathe 199
Zhejiang Chiral Medicine Chemicals To Acquire Stake In Actavis (Foshan) Pharma From Actavis 201
Teva Pharma Completes Acquisition of MicroDose Therapeutx 202
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 203
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 205
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 207
Teva Pharma Rumored To Acquire Amarin 208
Watson Pharma Acquires Ascent Pharmahealth From Strides Arcolab And Dennis Bastas For US$394 Million 209
Teva Pharmaceutical Industries Ltd, Key Competitors 211
Teva Pharmaceutical Industries Ltd, Key Employees 212
Teva Pharmaceutical Industries Ltd, Subsidiaries 214
Teva Pharmaceutical Industries Ltd, Joint Venture 223

List Of Figures

List of Figures
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 17

Teva Pharmaceuticals: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950View Report

Teva Pharmaceutical Industries Limited - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Teva Pharmaceutical Industries Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Teva Pharmaceutical Industries Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350View Report

Teva Pharmaceuticals: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950View Report

Teva Pharmaceutical Industries Limited - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Teva Pharmaceutical Industries Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Teva Pharmaceutical Industries Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes

USD 350View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :288
Country :Israel
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube